Literature DB >> 17981458

Almost all articles on cancer prognostic markers report statistically significant results.

Panayiotis A Kyzas1, Despina Denaxa-Kyza, John P A Ioannidis.   

Abstract

We aimed to understand the extent of the pursuit for statistically significant results in the prognostic literature of cancer. We evaluated 340 articles included in prognostic marker meta-analyses (Database 1) and 1575 articles on cancer prognostic markers published in 2005 (Database 2). For each article, we examined whether the abstract reported any statistically significant prognostic effect for any marker and any outcome ('positive' articles). 'Negative' articles were further examined for statements made by the investigators to overcome the absence of prognostic statistical significance. We also examined how the articles of Database 1 had presented the relative risks that were included in the respective meta-analyses. 'Positive' prognostic articles comprised 90.6% and 95.8% in Databases 1 and 2, respectively. Most of the 'negative' prognostic articles claimed significance for other analyses, expanded on non-significant trends or offered apologies that were occasionally remote from the original study aims. Only five articles in Database 1 (1.5%) and 21 in Database 2 (1.3%) were fully 'negative' for all presented results in the abstract and without efforts to expand on non-significant trends or to defend the importance of the marker with other arguments. Of the statistically non-significant relative risks in the meta-analyses, 25% had been presented as statistically significant in the primary papers using different analyses compared with the respective meta-analysis. We conclude that almost all articles on cancer prognostic marker studies highlight some statistically significant results. Under strong reporting bias, statistical significance loses its discriminating ability for the importance of prognostic markers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17981458     DOI: 10.1016/j.ejca.2007.08.030

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  73 in total

1.  STrengthening the reporting of OBservational studies in Epidemiology-Molecular Epidemiology (STROBE-ME): an extension of the STROBE statement.

Authors:  Valentina Gallo; Matthias Egger; Valerie McCormack; Peter B Farmer; John P A Ioannidis; Micheline Kirsch-Volders; Giuseppe Matullo; David H Phillips; Bernadette Schoket; Ulf Stromberg; Roel Vermeulen; Christopher Wild; Miquel Porta; Paolo Vineis
Journal:  Eur J Epidemiol       Date:  2011-10-29       Impact factor: 8.082

2.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  BMC Med       Date:  2012-05-29       Impact factor: 8.775

3.  Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.

Authors:  Douglas G Altman; Lisa M McShane; Willi Sauerbrei; Sheila E Taube
Journal:  PLoS Med       Date:  2012-05-29       Impact factor: 11.069

Review 4.  Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses.

Authors:  John P A Ioannidis
Journal:  CMAJ       Date:  2009-08-04       Impact factor: 8.262

5.  Strengthening the reporting of genetic risk prediction studies: the GRIPS statement.

Authors:  A Cecile Jw Janssens; John Pa Ioannidis; Cornelia M van Duijn; Julian Little; Muin J Khoury
Journal:  Genome Med       Date:  2011-03-15       Impact factor: 11.117

Review 6.  Combining a molecular profile with a clinical and pathological profile: biostatistical considerations.

Authors:  Richard J Sylvester
Journal:  Scand J Urol Nephrol Suppl       Date:  2008-09

7.  A call for transparent reporting to optimize the predictive value of preclinical research.

Authors:  Story C Landis; Susan G Amara; Khusru Asadullah; Chris P Austin; Robi Blumenstein; Eileen W Bradley; Ronald G Crystal; Robert B Darnell; Robert J Ferrante; Howard Fillit; Robert Finkelstein; Marc Fisher; Howard E Gendelman; Robert M Golub; John L Goudreau; Robert A Gross; Amelie K Gubitz; Sharon E Hesterlee; David W Howells; John Huguenard; Katrina Kelner; Walter Koroshetz; Dimitri Krainc; Stanley E Lazic; Michael S Levine; Malcolm R Macleod; John M McCall; Richard T Moxley; Kalyani Narasimhan; Linda J Noble; Steve Perrin; John D Porter; Oswald Steward; Ellis Unger; Ursula Utz; Shai D Silberberg
Journal:  Nature       Date:  2012-10-11       Impact factor: 49.962

Review 8.  Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines.

Authors:  S Mallett; A Timmer; W Sauerbrei; D G Altman
Journal:  Br J Cancer       Date:  2009-12-08       Impact factor: 7.640

9.  "Positive" results increase down the Hierarchy of the Sciences.

Authors:  Daniele Fanelli
Journal:  PLoS One       Date:  2010-04-07       Impact factor: 3.240

10.  Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours.

Authors:  Arne Westgaard; Aasa R Schjølberg; Milada Cvancarova; Tor J Eide; Ole Petter F Clausen; Ivar P Gladhaug
Journal:  Histopathology       Date:  2009-02       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.